FierceBiotech· @FierceBiotech · X·· 2 天前精选AI 评分68
AI 导读
Mirum Pharmaceuticals 的慢性丁型肝炎病毒在研药物 III 期试验达到主要终点，推动该公司进入这一近期由吉利德科学占据的领域。相关结果发布在 Fierce Biotech 的报道中，链接为 https://www.fiercebiotech.com/biotech/mirum-posts-phase-3-hepatitis-win-commercially-differentiated-challenger-gilead-and-vir。
推荐理由
Mirum 的慢性丁型肝炎在研药 III 期达到主要终点，读者可了解该领域继吉利德之后的竞争格局。
正文
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead Sciences. https://www.fiercebiotech.com/biotech/mirum-posts-phase-3-hepatitis-win-commercially-differentiated-challenger-gilead-and-vir
来源：FierceBiotech · x.com